Publicaciones en colaboración con investigadores/as de University of Alabama at Birmingham (10)

2023

  1. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

    Obesity, Vol. 31, Núm. 3, pp. 703-715

2022

  1. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

    Nature Medicine, Vol. 28, Núm. 10, pp. 2083-2091

2021

  1. Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism

    American Journal of Human Genetics, Vol. 108, Núm. 6, pp. 1138-1150

2020

  1. Epilepsy and Electroencephalographic Abnormalities in SATB2-Associated Syndrome

    Pediatric Neurology, Vol. 112, pp. 94-100

2019

  1. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911

  2. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies

    Calcified Tissue International, Vol. 104, Núm. 2, pp. 193-200

2018

  1. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies

    Bone, Vol. 116, pp. 58-66

2014

  1. Effect of evolocumab or ezetimibe added to moderate- Or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial

    JAMA, Vol. 311, Núm. 18, pp. 1870-1882

2013

  1. Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial

    Annals of Internal Medicine, Vol. 158, Núm. 9, pp. 641-649

2007

  1. Teriparatide or alendronate in glucocorticoid-induced osteoporosis

    New England Journal of Medicine, Vol. 357, Núm. 20, pp. 2028-2039